Galantamine
Treatment for Alzheimers Disease
Typical Dosage: 8-24 mg orally daily (extended-release)
Effectiveness
42%
Safety Score
58%
Clinical Trials
58
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
8-24 mg orally daily (extended-release)
Time to Effect
4-6 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
18(Treat 18 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$400
Side Effect Mgmt:$50
Total Annual:$550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.03
Outcome-Based Costs
Cost per Responder
$2,200
Galantamine Outcomes
for Alzheimers Disease
Efficacy Outcomes
Overall Effectiveness
+42%
Response Rate
+25%
Common Side Effects
Nausea
+13%
Vomiting
+8%
Anorexia
+7%
Diarrhea
+6%
Dizziness
+6%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
16 completed trials for Galantamine in Alzheimers Disease
A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
NCT01734395COMPLETED
1.88K participants
OBSERVATIONAL
Started: Mar 1, 2007
A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease
NCT00645190COMPLETEDPHASE3
215 participants
INTERVENTIONAL
Started: Mar 1, 2004
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
NCT01054976COMPLETEDPHASE4
99 participants
INTERVENTIONAL
Started: Oct 1, 2006
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
NCT00297362COMPLETED
344 participants
OBSERVATIONAL
Started: Jun 1, 2004
Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)
NCT01039194COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Baltimore, United States
Started: Jan 1, 2010
Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
NCT01478633COMPLETEDPHASE4
102 participants
INTERVENTIONAL
Akita, Japan +10 more
Started: Sep 1, 2011
A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.
NCT00309725COMPLETEDPHASE3
139 participants
INTERVENTIONAL
Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease
NCT00304629COMPLETEDPHASE3
241 participants
INTERVENTIONAL
Started: Mar 1, 2000
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
NCT00338117COMPLETEDPHASE3
554 participants
INTERVENTIONAL
Started: Aug 1, 1995
A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease
NCT00035204COMPLETEDPHASE4
63 participants
INTERVENTIONAL
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
NCT00216593COMPLETEDPHASE3
415 participants
INTERVENTIONAL
Started: Dec 1, 2003
Evaluation of Galantamine in the Treatment of Alzheimer's Disease
NCT00000172COMPLETEDPHASE3
INTERVENTIONAL
Birmingham, United States +54 more
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.
NCT00301574COMPLETEDPHASE3
398 participants
INTERVENTIONAL
Started: Apr 1, 2001
The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
NCT00216515COMPLETEDPHASE4
102 participants
INTERVENTIONAL
Started: Mar 1, 2004
Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation
NCT00253214COMPLETEDPHASE3
973 participants
INTERVENTIONAL
Started: Mar 1, 2001
Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
NCT00082602COMPLETEDPHASE3
83 participants
INTERVENTIONAL
Started: May 1, 2004
Showing 20 of 58 total trials